Literature DB >> 12044925

Hyperandrogenaemia and the ovary.

Robert J Norman1.   

Abstract

Hyperandrogenaemia in women presents in a variety of ways, including problems with the reproductive system. The commonest cause is polycystic ovary syndrome (PCOS), a condition found in 5-10% of all women. PCOS has origins that are genetic and environmental but the end organ, the ovary, exhibits excessive androgen production with enhanced sensitivity to luteinising hormone and insulin. Interventions include approaches that target both these hormones as well as the ovary itself.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044925     DOI: 10.1016/s0303-7207(02)00062-x

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  4 in total

1.  Premature ovarian failure in androgen receptor-deficient mice.

Authors:  Hiroko Shiina; Takahiro Matsumoto; Takashi Sato; Katsuhide Igarashi; Junko Miyamoto; Sayuri Takemasa; Matomo Sakari; Ichiro Takada; Takashi Nakamura; Daniel Metzger; Pierre Chambon; Jun Kanno; Hiroyuki Yoshikawa; Shigeaki Kato
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-22       Impact factor: 11.205

2.  Basal serum level of Δ4-androstenedione reflects the ovaries' ability to respond to stimulation in IVF cycles: setting up a new reliable index of both ovarian reserve and response.

Authors:  Emanuele Garzia; Valentina Galiano; Laura Guarnaccia; Giovanni Marfia; Giulia Murru; Ellade Guermandi; Jennifer Riparini; Patrizia Sulpizio; Anna Maria Marconi
Journal:  J Assist Reprod Genet       Date:  2022-06-27       Impact factor: 3.357

3.  LH/hCG-stimulated androgen production and selective HDL-cholesterol transport are inhibited by a dominant-negative CREB construct in primary cultures of rat theca-interstitial cells.

Authors:  Roberto Towns; Salman Azhar; Helle Peegel; K M J Menon
Journal:  Endocrine       Date:  2005-08       Impact factor: 3.925

4.  Comparison of GnRH agonist versus luteal estradiol GnRH antagonist protocol using transdermal testosterone in poor responders.

Authors:  Francesc Fàbregues; Roser Solernou; Janisse Ferreri; Marta Guimerá; Sara Peralta; Gemma Casals; Joana Peñarrubia; Montserrat Creus; Dolors Manau
Journal:  JBRA Assist Reprod       Date:  2019-04-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.